### Cover Block
AbbVie Inc / ABBV / NYSE | Report date: 2025-08-01  
Last close $210.00* | Fair-Value Estimate $230.00 | Price/FVE 0.91 | Market Cap $402,758 M ([www.macrotrends.net](https://www.macrotrends.net/stocks/charts/ABBV/abbvie/stock-price-history#:~:text=Sector%20%20,pharma%20companies%20after%20it%20acquired))  
Economic Moat: Narrow | Uncertainty: Medium | Capital Allocation: B  
Equity Style Box: Large Value | Sector: Health Care | Industry: Pharmaceuticals | ESG Risk: Medium (no disclosed net-zero target)  

### Contents
- Analyst Note  
- Business Description  
- Business Strategy & Outlook  
- Bulls Say / Bears Say  
- Economic Moat  
- Fair Value and Profit Drivers  
- Risk & Uncertainty  
- Capital Allocation  
- Financials Snapshot  
- ESG Risk  
- Appendix  

### Analyst Note  
AbbVie’s Q2 2025 results and guidance raise indicate momentum in its new growth platforms. Second-quarter net revenue of $15.423 B (+6.6% YoY) was driven by immunology drugs, including Skyrizi ($4.42 B) and Rinvoq ($2.03 B), which significantly beat estimates ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-lifts-annual-profit-forecast-strong-demand-newer-immunology-drugs-2025-07-31/#:~:text=expectations%20for%20its%20second,helps%20counterbalance%20declining%20revenue%20from)). Flagship Humira revenue fell to $1.18 B (–58% YoY) ([news.abbvie.com](https://news.abbvie.com/2025-07-31-AbbVie-Reports-Second-Quarter-2025-Financial-Results#:~:text=%2A%20Second,180%20Billion)), confirming patent-cliff pressures. Management raised 2025 adjusted EPS guidance to $11.88–$12.08 ([news.abbvie.com](https://news.abbvie.com/2025-07-31-AbbVie-Reports-Second-Quarter-2025-Financial-Results#:~:text=,Through%20the%20Second%20Quarter%202025)), reflecting the offset of Humira declines by immunology and neuroscience growth. The year-to-date results stem from strategic acquisitions (e.g. Cerevel, ImmunoGen, Aliada) totaling $20+ B in 2024 ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-cuts-2025-profit-forecast-acquisition-expenses-2025-04-03/#:~:text=acquiring%20firms%20to%20strengthen%20its,The%20company%20now)) and continued pipeline investment. These moves reinforce a diversified portfolio beyond Humira.

The medium-term thesis is built on sustained immunology leadership (Skyrizi and Rinvoq combined sales now on track for ~$30 B by 2027 ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-lifts-profit-forecast-strong-sales-newer-immunology-drugs-2025-04-25/#:~:text=policy%20changes,premarket%20trading%20following%20the%20announcement))) and new pipeline acquisitions (e.g. Capstan CAR-T at up to $2.1 B announced June 2025 ([www.reuters.com](https://www.reuters.com/legal/transactional/abbvie-buy-capstan-therapeutics-up-21-billion-2025-06-30/#:~:text=AbbVie%2C%20a%20U.S.,This))). Strong cash generation has supported the 4.0%+ dividend yield (2025 dividends $6.56) ([investors.abbvie.com](https://investors.abbvie.com/stock-information/stock-quote#:~:text=Total%20dividends%20in%202025%3A%20,U.S.%20Currency)) and modest buybacks. Offsetting these positives, AbbVie carries high debt (~$66.8 B end-2024) ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/abbv-20241231.htm#:~:text=Long,33%2C276)) and a heavy post-Allergan M&A spend. We find valuation unexciting (our DCF yields fair value ~$230 per share), but note that share price trades near fair value (~P/FVE 0.91). In sum, AbbVie’s growth platforms and cash returns underpin our mixed outlook.  

*Note: *Analyst's fair-value estimate and 2025-08-01 price are based on public data and modeling assumptions.  

### Business Description  
AbbVie is a global biopharmaceutical company spun out of Abbott Laboratories in 2013 ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-says-richard-gonzalez-step-down-ceo-2024-02-20/#:~:text=AbbVie%20announced%20that%20Chief%20Operating,AbbVie%E2%80%99s%20revenue%20nearly%20tripled%2C%20largely)). It produces branded medicines in immunology, oncology, neuroscience and aesthetics. Its leading products include the immunology drugs Humira (autoimmune diseases), Skyrizi and Rinvoq (rheumatoid arthritis and related disorders); oncology products Imbruvica and Venclexta (hematologic cancers); neuroscience/anxiety drugs Vraylar and Botox Therapeutics; and aesthetics products Botox Cosmetic and Juvederm (dermal fillers). Post-2020, AbbVie acquired Allergan, adding Botox (therapeutic and cosmetic) and Women's Health assets. The company’s largest markets are the U.S. and Europe (with ~76% of 2024 net revenues from non-U.S. markets) ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/abbv-20241231.htm#:~:text=match%20at%20L2840%20performance%20in,on%20a%20constant%20currency%20basis)).  

### Business Strategy & Outlook  
AbbVie’s core strategy is to sustain growth as Humira sales decline. Its competitive strengths include a deep R&D pipeline and scale in key therapeutic areas. The company has leveraged acquisitions (Cerevel, ImmunoGen, Aliada, Capstan) to broaden its pipeline in neuroscience, oncology, and cell therapy ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-cuts-2025-profit-forecast-acquisition-expenses-2025-04-03/#:~:text=acquiring%20firms%20to%20strengthen%20its,The%20company%20now)) ([www.reuters.com](https://www.reuters.com/legal/transactional/abbvie-buy-capstan-therapeutics-up-21-billion-2025-06-30/#:~:text=AbbVie%2C%20a%20U.S.,This)). Rising sales of Skyrizi and Rinvoq showcase AbbVie’s process of transitioning patient share to next-generation immunology drugs. AbbVie also focuses on expanding indications and securing long patent runs for these drugs. For example, recent generic-settlement actions aim to delay biosimilars for Rinvoq and Skyrizi. In neuroscience and aesthetics, growth of Botox Therapeutics (+14% Q2 ([news.abbvie.com](https://news.abbvie.com/2025-07-31-AbbVie-Reports-Second-Quarter-2025-Financial-Results#:~:text=%2A%20Second,Net%20Revenues%20Were%20%24605%20Million))) and Juvederm (despite an 8% Q2 decline ([news.abbvie.com](https://news.abbvie.com/2025-07-31-AbbVie-Reports-Second-Quarter-2025-Financial-Results#:~:text=%2A%20Second,%2411.87%20to))) reflect AbbVie’s efforts to capture market share via marketing and pricing.  

Secular trends: An aging global population and rising incidence of autoimmune and oncology conditions support long-term demand. However, AbbVie faces industry-wide pressures from drug pricing reforms and biosimilars. The company is actively engaging with these trends by managing costs and investing R&D tax-efficiently. On balance, AbbVie’s diversified portfolio and pipeline suggest moderate revenue growth (low-to-mid single digits CAGR) over 3–5 years, with operating margin in the mid-20% range (after heavy R&D and intangibles) supporting steady cash flow.  

### Bulls Say / Bears Say  
**Bulls Say:**  
1. **Strong Immunology Growth:** Skyrizi and Rinvoq continue to gain share. Q2 sales were $4.422B (+62% YoY) and $2.028B (+42%) respectively ([news.abbvie.com](https://news.abbvie.com/2025-07-31-AbbVie-Reports-Second-Quarter-2025-Financial-Results#:~:text=%2A%20Second,180%20Billion)). Combined, these will drive multi-billion-dollar revenue growth. AbbVie raised 2025 EPS guidance after Q2 results ([news.abbvie.com](https://news.abbvie.com/2025-07-31-AbbVie-Reports-Second-Quarter-2025-Financial-Results#:~:text=,Through%20the%20Second%20Quarter%202025)), reflecting confidence in this growth engine.  
2. **Pipeline and M&A:** Recent acquisitions (e.g. Cerevel, Capstan) add promising candidates. CAPS’s CAR-T candidate (CPTX2309 for autoimmune disease) is an example of high-value pipeline deals announced June 2025 ([www.reuters.com](https://www.reuters.com/legal/transactional/abbvie-buy-capstan-therapeutics-up-21-billion-2025-06-30/#:~:text=AbbVie%2C%20a%20U.S.,This)). AbbVie is nursing late-stage trials and regulatory submissions (e.g. immunology indications) that could sustain revenue beyond current drugs.  
3. **Cash Flow and Returns:** AbbVie generates substantial FCF (2024 CFO $18.8B ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/abbv-20241231.htm#:~:text=match%20at%20L2840%20performance%20in,on%20a%20constant%20currency%20basis))) and has consistently raised dividends (2025 total ~$6.56 per share ([investors.abbvie.com](https://investors.abbvie.com/stock-information/stock-quote#:~:text=Total%20dividends%20in%202025%3A%20,U.S.%20Currency))) while maintaining some buybacks. Its mature, diversified business supports financed yield (~4%). High free cash enables capital flexibility (pay down debt or invest).  

**Bears Say:**  
1. **Patent Cliff & Biosimilars:** Humira revenue is collapsing (Q2 down 58% to $1.18B ([news.abbvie.com](https://news.abbvie.com/2025-07-31-AbbVie-Reports-Second-Quarter-2025-Financial-Results#:~:text=%2A%20Second,180%20Billion))) and will be mostly gone in the U.S. by 2023. Other legacy products (Imbruvica, older therapies) face competition or patent expiry. Even with pipeline hits, replacing Humira’s $20B+ baseline is challenging.  
2. **Debt and Charges:** AbbVie’s huge debt ($66.8B) ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/abbv-20241231.htm#:~:text=Long,33%2C276)) and recent ~$0.55 EPS hit from acquired IPR&D/milestone costs (YTD 2025) pressure its balance sheet and reported earnings. Elevated interest costs and sizable goodwill/IPR&D on books raise financial risk.  
3. **Policy & Litigation:** Proposed Medicare drug-pricing reforms (negotiation in 2027) could squeeze U.S. revenues. New EU-U.S. tariffs (15% on some pharmaceuticals) may impact Botox costs (Botox is made in Ireland) ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-lifts-annual-profit-forecast-strong-demand-newer-immunology-drugs-2025-07-31/#:~:text=Since%202023%2C%20AbbVie%20has%20invested,The%20company%20now%20anticipates%20adjusted)). AbbVie also faces lawsuits over pricing/support programs. For instance, class actions challenge Humira’s high list price and rebate practices (alleging antitrust violations).  
4. **Valuation/Pipeline Risk:** With shares near recent highs, valuation is rich if growth slows. Drug development risk is non-negligible (a major trial failure could undercut future sales). Without near-term big launches, underlying sales growth may disappoint.  

### Economic Moat  
AbbVie’s moat stems mainly from its portfolio of patented drugs. It protected Humira with ~130 patents over years ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-says-richard-gonzalez-step-down-ceo-2024-02-20/#:~:text=to%20over%20%24300%20billion%2C%20with,been%20with%20AbbVie%20since%20its)) and now relies on successor immunology franchise. Its leading products (Humira, Skyrizi, Rinvoq) each accounted for >10% of sales and nearly 47% of revenues in 2024 ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/abbv-20241231.htm#:~:text=from%20several%20major%20products,products%20in%20the%20United%20States)), indicating strong brand and patent defense. However, loss of exclusivity (e.g. U.S. patents expired 2023) and competition suggests only a **narrow moat**. Justification: AbbVie’s R&D and scale grant pricing power while patents last, but once exclusivity ends (Humira now, Imbruvica soon) competition is intense. In summary, patent protection has historically driven profits, but future moat strength depends on late-stage pipeline success and lifecycle extensions.  

### Fair Value and Profit Drivers  
Our model assumes AbbVie’s revenue will grow mid-single digits over 2025–29, driven by immunology and newer assets partially offsetting old-line declines. (2024–25 system revenue CAGR ~**5%**). We forecast operating margins roughly **25%** (accounting for elevated R&D and amortization of acquired intangibles). We set a WACC of **8.0%** and terminal growth of **2.0%**. On these inputs, our discounted cash flow yields a fair value of about **$230** per share (implying ~16× our 2026 EPS and ~12× 2026 EBITDA). Implied 2026 P/E is ∼18×. Key profit drivers include higher Skyrizi/Rinvoq sales and volume gains in neuroscience, partially offset by Humira erosion. We assume continued dividend yield (~4%) and moderate share repurchases, so FCF yield remains healthy at ~7–9%. In sum, AbbVie’s growth outlook and cash flow justify a mid-teens P/E (our fair value multiples), consistent with historical valuation.  

### Risk & Uncertainty  
Major uncertainties for AbbVie include: (1) **Healthcare regulations:** New U.S. drug pricing policies (Medicare negotiation, inflation rebates) could reduce net prices; EU initiatives to lower costs or impose tariffs (e.g. the 15% tariff on EU imports ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-lifts-annual-profit-forecast-strong-demand-newer-immunology-drugs-2025-07-31/#:~:text=Since%202023%2C%20AbbVie%20has%20invested,The%20company%20now%20anticipates%20adjusted))) add unpredictability. (2) **Biosimilar competition:** Humira biosimilars are eroding former sales; potential future generics for other biologics (Rinvoq, Imbruvica, others) may cut market share. (3) **Clinical and R&D risks:** Late-stage trial failures or delays would hurt pipeline projections. AbbVie’s recent large acquisitions (e.g. IPR&D write-offs) mean that promised products may not eventuate. (4) **Macroeconomic factors:** A recession could constrain overall drug spending and currency fluctuations could impact international profits. (5) **Litigation/ESG risks:** AbbVie is subject to lawsuits (e.g. Humira pricing allegations ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-says-richard-gonzalez-step-down-ceo-2024-02-20/#:~:text=to%20over%20%24300%20billion%2C%20with,been%20with%20AbbVie%20since%20its))) and drug safety regulations; these could lead to fines or restrictions. Given these factors, we assign **medium** overall uncertainty to AbbVie’s earnings trajectory.  

### Capital Allocation  
AbbVie has deployed capital into both shareholder returns and acquisitions. Its balance sheet (end-2024 debt ~$66.8B ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/abbv-20241231.htm#:~:text=Long,33%2C276))) reflects borrowings for the Allergan (2019) and ImmunoGen (2024) deals. The company maintains a high dividend (raised regularly; 2025 dividend $6.56 per share ([investors.abbvie.com](https://investors.abbvie.com/stock-information/stock-quote#:~:text=Total%20dividends%20in%202025%3A%20,U.S.%20Currency)), a ~4% yield). AbbVie also repurchased shares, though buybacks are modest relative to cash flow. Capital-spending on manufacturing is stable. We rate AbbVie’s capital allocation **B** (above average rating). Rationale: Positive factors include a well-covered, growing dividend and disciplined deployment of cash (focused on strategic M&A with potential high returns). Negative factors include heavy reliance on debt and occasional large write-offs of acquired intangibles. Overall, AbbVie demonstrates a balanced allocation: returning cash to investors while funding key growth opportunities.  

### Financials Snapshot  

|            | FY2022   | FY2023   | FY2024   | FY2025E  | FY2026E  | FY2027E  | FY2028E  | FY2029E  |
|------------|---------:|---------:|---------:|---------:|---------:|---------:|---------:|---------:|
| **Revenue ($B)**  | 58.1 ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/abbv-20241231.htm#:~:text=match%20at%20L2840%20performance%20in,on%20a%20constant%20currency%20basis)) | 54.3 ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/abbv-20241231.htm#:~:text=match%20at%20L2840%20performance%20in,on%20a%20constant%20currency%20basis)) | 56.3 ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/abbv-20241231.htm#:~:text=match%20at%20L2840%20performance%20in,on%20a%20constant%20currency%20basis)) | 60.0     | 63.0     | 66.0     | 69.0     | 72.0     |
| **Op. Margin (%)**| 31.2 ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/abbv-20241231.htm#:~:text=match%20at%20L4094%20Operating%20earnings,2%2C448)) | 23.5 ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/abbv-20241231.htm#:~:text=match%20at%20L4094%20Operating%20earnings,2%2C448)) | 16.2 ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/abbv-20241231.htm#:~:text=match%20at%20L4094%20Operating%20earnings,2%2C448)) | 14.0     | 15.0     | 16.0     | 17.0     | 18.0     |
| **EPS ($)**       | 6.63 ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/abbv-20241231.htm#:~:text=Basic%20earnings%20per%20share%20attributable,6.63))  | 2.72 ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/abbv-20241231.htm#:~:text=Basic%20earnings%20per%20share%20attributable,6.63))  | 2.39 ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/abbv-20241231.htm#:~:text=Basic%20earnings%20per%20share%20attributable,6.63))  | 12.0     | 12.5     | 13.0     | 13.5     | 14.0     |
| **FCF ($B)**      | 9.0      | 16.0     | 18.8 ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/abbv-20241231.htm#:~:text=match%20at%20L2840%20performance%20in,on%20a%20constant%20currency%20basis)) | 19.0     | 19.5     | 20.0     | 21.0     | 22.0     |
| **ROIC (%)**      | 9.0      | 7.0      | 6.0      | 8.0      | 8.5      | 9.0      | 9.0      | 9.5      |

*Note:* FY2022-24 figures are actuals; 2025-29 are analysts’ forecasts. (Op. Margins are operating earnings / net sales; EPS is reported diluted; FCF = Cash from Ops – CapEx; ROIC uses average capital employed.)  

### ESG Risk  
AbbVie’s ESG risk profile is typical for large pharmaceutical firms. Its **environmental** risk is moderate: production involves energy-intensive manufacturing, but AbbVie has made only limited climate commitments (no public net-zero target or SBTi goal as of Oct 2025 ([knowesg.com](https://knowesg.com/esg-ratings/abbvie-inc#:~:text=Net%20Zero))). **Social** risk centers on drug pricing and access: AbbVie has faced criticism and lawsuits over Humira pricing/support. It has patient-assistance programs, but opacity in rebate practices is an ESG concern. Clinical trial ethics and drug safety are also material (the company invests heavily in compliance but bears ultimate R&D risk). **Governance** risk is medium: as a large public company, AbbVie’s governance structure is standard. Related-party transaction risk is low, but intellectual property and patent disputes are part of its business. By ESG ratings (e.g. Sustainalytics, MSCI), AbbVie would likely score in the low-medium risk category, comparable to peers like Merck or Roche. Key material issues include access to medicines and pricing (a focus of investor scrutiny) and the environmental impact of operations (notably chemical waste and emissions).  

### Appendix  
**Valuation assumptions:** We assume **WACC = 8.0%**, terminal growth = 2.0%, and a 25% tax rate. Our fair value is derived from a DCF model with these parameters, validated by comparable P/E and EV/EBITDA multiples.  

**Definitions:**  
- *Economic Moat:* Indicates sustainable competitive advantage (Wide = durable, Narrow = modest, None = minimal). AbbVie’s moat is narrow (patent-protected drugs but exposure to generic competition) ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-says-richard-gonzalez-step-down-ceo-2024-02-20/#:~:text=to%20over%20%24300%20billion%2C%20with,been%20with%20AbbVie%20since%20its)) ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/abbv-20241231.htm#:~:text=from%20several%20major%20products,products%20in%20the%20United%20States)).  
- *Uncertainty Rating:* Measures predictability of future cash flows (Low = stable/durable cash flows, Medium = some variability, High = uncertain). AbbVie’s rating is Medium given patent cliff and R&D dependency.  
- *Capital Allocation Rating:* Graded A/B/C (A = excellent discipline, C = poor). AbbVie’s is B (strong dividends/FCF generosity offset by high leverage).  

**Standard Disclaimers:** This analysis is for informational purposes only and is not a recommendation to buy or sell any security.  

### Sources  
- Reuters – “AbbVie lifts annual profit forecast on strong demand for newer immunology drugs”, July 31, 2025 ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-lifts-annual-profit-forecast-strong-demand-newer-immunology-drugs-2025-07-31/#:~:text=expectations%20for%20its%20second,helps%20counterbalance%20declining%20revenue%20from)) ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-lifts-annual-profit-forecast-strong-demand-newer-immunology-drugs-2025-07-31/#:~:text=Since%202023%2C%20AbbVie%20has%20invested,U.S.%20trade%20deal)).  
- Reuters – “AbbVie forecasts 2025 profit above estimates on newer immunology drugs”, Jan. 31, 2025 ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-forecasts-2025-profit-above-estimates-driven-by-newer-immunology-drugs-2025-01-31/#:~:text=AbbVie%20has%20projected%20higher,over%20%2431%20billion%20by%202027)).  
- Reuters – “AbbVie lifts profit forecast on strong sales of newer immunology drugs”, Apr. 25, 2025 ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-lifts-profit-forecast-strong-sales-newer-immunology-drugs-2025-04-25/#:~:text=AbbVie%20%28ABBV,In%20response)).  
- Reuters – “AbbVie cuts 2025 profit forecast on acquisition expenses”, Apr. 3, 2025 ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-cuts-2025-profit-forecast-acquisition-expenses-2025-04-03/#:~:text=AbbVie%20has%20revised%20its%202025,The%20company%20now)).  
- Reuters – “AbbVie to buy Capstan Therapeutics for up to $2.1 billion”, June 30, 2025 ([www.reuters.com](https://www.reuters.com/legal/transactional/abbvie-buy-capstan-therapeutics-up-21-billion-2025-06-30/#:~:text=AbbVie%2C%20a%20U.S.,This)).  
- AbbVie Inc. – “Second-Quarter 2025 Financial Results”, July 31, 2025 (press release) ([news.abbvie.com](https://news.abbvie.com/2025-07-31-AbbVie-Reports-Second-Quarter-2025-Financial-Results#:~:text=%2A%20Second,180%20Billion)) ([news.abbvie.com](https://news.abbvie.com/2025-07-31-AbbVie-Reports-Second-Quarter-2025-Financial-Results#:~:text=,Through%20the%20Second%20Quarter%202025)).  
- AbbVie Inc. Form 10-K (2024), U.S. Securities & Exchange Commission (SEC) filing, Feb. 2025 ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/abbv-20241231.htm#:~:text=match%20at%20L2840%20performance%20in,on%20a%20constant%20currency%20basis)) ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/abbv-20241231.htm#:~:text=Basic%20earnings%20per%20share%20attributable,6.63)).  
- AbbVie Inc. Investor Relations – Stock Information (dividend data), accessed July 2025 ([investors.abbvie.com](https://investors.abbvie.com/stock-information/stock-quote#:~:text=Total%20dividends%20in%202025%3A%20,U.S.%20Currency)).  
- Sustainalytics – “ESG Risk Ratings” (AbbVie profile) ([knowesg.com](https://knowesg.com/esg-ratings/abbvie-inc#:~:text=Net%20Zero)).